Characteristics and demographics of reversible cerebral vasoconstriction syndrome: A large prospective series of Korean patients
Abstract
Objectives
Methods
Results
Conclusion
Introduction
Methods
Clinical and radiological evaluation
Follow-up of patients with RCVS
Statistical analyses
Results
Demographics and characteristics of RCVS

| Definite RCVS (n = 104) | Probable RCVS (n = 34) | p | |
|---|---|---|---|
| Age (years) | 50.7 ± 12.17 | 52.0 ± 12.69 | 0.43 |
| Female sex | 89 (85.6%) | 24 (70.6%) | 0.049 |
| Modes of recruitment | 0.12 | ||
| Outpatient clinic | 57 (54.8%) | 25 (73.5%) | |
| Emergency center | 41 (39.4%) | 9 (26.5%) | |
| Inpatient consultation | 6 (5.8%) | 0 (0.0%) | |
| Onset to visit (days) | 8.0 (4.3–27.8) | 15.0 (5.5–40.3) | 0.23 |
| Associated conditions | |||
| Hypertension | 20 (19.2%) | 8 (23.5%) | 0.59 |
| Cardiac diseases | 8 (7.7%) | 2 (5.9%) | >0.99 |
| Autoimmune diseases | 2 (1.9%) | 0 (0.0%) | >0.99 |
| Smoking | 4 (3.8%) | 5 (14.7%) | 0.041 |
| Premorbid migraine | 17 (16.8%) | 6 (17.6%) | 0.91 |
| Causes of RCVS | 0.37 | ||
| Idiopathic | 88 (84.6%) | 31 (91.2%) | |
| Postpartum | 6 (5.8%) | 0 (0.0%) | |
| Medication | 6 (5.8%) | 3 (8.8%) | |
| Others* | 4 (3.8%) | 0 (0.0%) | |
| Headache characteristics** | |||
| Thunderclap | 90 (89.1%) | 34 (100.0%) | 0.065 |
| Recurrent thunderclap | 71 (70.3%) | 34 (100.0%) | <0.001 |
| Self-limited | 82 (81.2%) | 24 (70.6%) | 0.19 |
| Triggered by typical precipitants | |||
| The first thunderclap headache triggered by at least one precipitant | 65 (64.4%) | 28 (82.4%) | 0.05 |
| At least one thunderclap headache triggered by at least one precipitant | 72 (71.3%) | 34 (100.0%) | <0.001 |
| Triggered by multiple precipitants | 37 (36.6%) | 14 (41.2%) | 0.69 |
| No new significant headache at one month after onset | 98 (97.0%) | 34 (100.0%) | 0.57 |
| Focal deficits | 6 (5.8%) | 0 (0.0%) | 0.34 |
| BP surge† | 42 (61.8%) | 8 (47.1%) | 0.27 |
| Onset to neuroimaging (days)‡ | 7.0 (3.0–14.0) | 11.5 (2.0–21.0) | 0.21 |
| Onset to neuroimaging (weeks) | 0.048 | ||
| 1st week after onset | 57 (54.8%) | 13 (38.2%) | |
| 2nd week after onset | 22 (21.2%) | 6 (17.6%) | |
| 3rd week after onset | 11 (10.6%) | 7 (20.6%) | |
| 4th week after onset | 2 (1.9%) | 1 (2.9%) | |
| >4th week after onset | 12 (11.5%) | 7 (20.6%) | |
| Neurological complications | |||
| Seizure | 3 (2.9%) | 0 (0.0%) | >0.99 |
| Infarction | 6 (6.3%) | 0 (0.0%) | 0.34 |
| Cortical SAH | 7 (7.4%) | 0 (0.0%) | 0.19 |
| PRES | 5 (5.3%) | 0 (0.0%) | 0.33 |
Diagnosis of RCVS in patients with or without headache
| ICHD-3 beta 6.7.3 headache attributed to RCVS | n (%) |
|---|---|
| A. Any new headache fulfilling criterion C | 101 (100.0%)* |
| B. RCVS has been diagnosed | 101 (100.0%) |
| C. Evidence of causation demonstrated by at least one of the following | |
| C1. Headache, with/without focal deficits and/or seizures, had led to angiography and diagnosis of RCVS | 101 (100.0%) |
| C2. Headache has either or both of the following characteristics | |
| a) recurrent during <1 month, and with thunderclap onset | 71 (70.3%) |
| b) Triggered by typical precipitants | 72 (71.3%) |
| One of a and b | 23 (22.8%) |
| Both of a and b | 60 (59.4%) |
| Neither of a and b | 18 (17.8%) |
| C3. No new significant headache at one month after onset | 98 (97.0%) |
| D. Not better accounted for by another ICHD-3 diagnosis, and aneurysmal subarachnoid haemorrhage has been excluded by appropriate investigations. | 101 (100.0%) |
| ICHD-3 beta 6.7.3.1 headache probably attributed to RCVS | n (%) |
|---|---|
| A. Any new headache fulfilling criterion C | 34 (100.0%) |
| B. RCVS is suspected, but cerebral angiography is normal | 34 (100.0%) |
| C. Probability of causation demonstrated by all of the following | 34 (100.0%) |
| C1. At least two headaches within one month, with all three of the following characteristics | 34 (100.0%) |
| a) thunderclap onset, and peaking in <1 minute | 34 (100.0%) |
| b) severe intensity | 34 (100.0%) |
| c) lasting ≥5 minutes | 34 (100.0%) |
| C2. At least one thunderclap headache has been triggered by one of the following | 34 (100.0%) |
| a) Sexual activity | 4 (11.8%) |
| b) Exertion | 7 (20.6%) |
| c) Valsalva-like maneuver | 14 (41.2%) |
| d) Emotion | 5 (14.7%) |
| e) Bathing and/or showering | 5 (14.7%) |
| f) Bending | 14 (41.2%) |
| C3. No new significant headache at one month after onset | 34 (100.0%) |
| D. Not fulfilling ICHD-3 criteria for any other headache disorder | 34 (100.0%) |
| E. Not better accounted for by another ICHD-3 diagnosis, and aneurysmal subarachnoid haemorrhage has been excluded by appropriate investigations. | 34 (100.0%) |

Conditions precipitating RCVS
| Total (n = 16)* | |
|---|---|
| Postpartum | 5 (31.3%) |
| Medications | 6 (37.5%) |
| Triptan | 1 (6.3%) |
| Adrenergic medication | 1 (6.3%) |
| Selective serotonin reuptake inhibitor | 1 (6.3%) |
| Bromocriptine | 1 (6.3%) |
| Illicit drug | 0 (0%) |
| Tacrolimus | 2 (12.5%) |
| Miscellaneous | 4 (25.0%) |
| Dissection** | 3 (18.8%) |
| Carotid bypass | 1 (6.3%) |
| Total (n = 33)* | |
|---|---|
| Lifestyle change | |
| Start of exercise within one month | 7 (21.2%) |
| Aerobic exercise | 3 |
| Boxing | 1 |
| Swimming | 1 |
| Anaerobic exercise | 1 |
| Bowing | 1 |
| Environmental change | |
| Exposure to cold weather | 3 (9.1%) |
| Immediately after a meal | 5 (15.2%) |
| Raw fish | 1 |
| Webfoot octopus with spicy seasoning | 1 |
| Unspecified | 3 |
| Emotional change | |
| Death of someone close | 3 (9.1%) |
| Stressful conditions | 8 (24.2%) |
| Health-related change | |
| Hormone replacement therapy | 2 (6.1%) |
| Systemic infection | 2 (6.1%) |
| Infectious colitis | 2 |
| Medical procedures (endoscopy, general anesthesia) | 2 (6.1%) |
Factors related to idiopathic RCVS
| Idiopathic (n = 88)* | Secondary (n = 16)* | p-value | |
|---|---|---|---|
| Age (years) | 52.8 ± 11.42 | 39.1 ± 9.55 | <0.001 |
| Female sex | 74 (84.1%) | 15 (93.8%) | 0.46 |
| Modes of recruitment | 0.023 | ||
| Outpatient clinic | 52 (59.1%) | 5 (31.3%) | |
| Emergency center | 33 (37.5%) | 8 (50.0%) | |
| Inpatient consultation | 3 (3.4%) | 3 (18.8%) | |
| Onset to visit (days) | 10.5 (4.0–30.0) | 7.0 (5.3–14.0) | 0.37 |
| Associated conditions | |||
| Hypertension | 17 (19.3%) | 3 (18.8%) | >0.99 |
| Cardiac disease | 6 (6.8%) | 2 (12.5%) | 0.61 |
| Autoimmune diseases | 0 (0.0%) | 2 (12.5%) | 0.022 |
| Smoking | 4 (4.5%) | 0 (0.0%) | >0.99 |
| Premorbid migraine | 15 (17.0%) | 2 (12.5%) | >0.99 |
| Headache characteristics† | |||
| Thunderclap | 78 (89.7%) | 12 (85.7%) | 0.65 |
| Recurrent | 62 (71.3%) | 9 (64.3%) | 0.75 |
| Self-limited | 73 (83.9%) | 9 (64.3%) | 0.13 |
| Triggered by typical precipitants | |||
| By at least one precipitant (at onset) | 57 (65.5%) | 8 (57.1%) | 0.56 |
| By at least one precipitant (anytime) | 64 (73.6%) | 8 (57.1%) | 0.22 |
| By multiple precipitants | 32 (36.8%) | 5 (35.7%) | 0.40 |
| Focal deficits | 4 (4.5%) | 2 (12.5%) | >0.99 |
| BP surge‡ | 33 (60.0%) | 9 (69.2%) | 0.75 |
| Onset to neuroimaging | 7.0 (3.0–15.8) | 7.0 (3.3–8.0) | 0.58 |
| Neurological complications** | |||
| Any | 10 (12.5%) | 6 (40.5%) | 0.018 |
| Seizure | 0 (0.0%) | 3 (18.8%) | 0.003 |
| Infarction | 3 (3.8%) | 3 (20.0%) | 0.048 |
| Cortical SAH | 4 (5.0%) | 3 (20.0%) | 0.072 |
| PRES | 3 (3.8%) | 2 (13.3%) | 0.18 |
| Treatment | 67 (76.1%) | 13 (81.3%) | 0.76 |
Treatment of RCVS
Discussion
Conclusions
Declaration of conflicting interests
Funding
Clinical implications
References
Cite article
Cite article
Cite article
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In

Keywords
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 726
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 36 view articles Opens in new tab
Crossref: 46
- Recurrent reversible cerebral vasoconstriction syndrome and antiphosph...
- Reversible cerebral Vasoconstriction syndrome intERnational Collaborat...
- Reversible cerebral vasoconstriction syndrome: A review of pathogenesi...
- Headache Attributed to Reversible Cerebral Vasoconstriction Syndrome (...
- Pediatric Reversible Cerebral Vasoconstriction Syndrome Related to Pre...
- Posterior Reversible Leucoencephalopathy Syndrome: Case Series, Commen...
- Complications of reversible cerebral vasoconstriction syndrome in rela...
- Reversible cerebral vasoconstriction syndrome: a clinical and therapeu...
- RCVS: by clinicians for clinicians—a narrative review
- Reversible Cerebral Vasoconstriction Syndrome Presenting with Thunderc...
- Reversible cerebral vasoconstriction syndrome and ischemic stroke
- Reversible Cerebral Vasoconstriction Syndrome and Its Complications
- Pathophysiology of reversible cerebral vasoconstriction syndrome
- Uncommon Female-Predominant Etiologies of Cryptogenic Stroke
- Reversible Cerebral Vasoconstriction Syndromes
- Type of headache at onset and risk for complications in reversible cer...
- Diagnostic Value of Thunderclap Headache and Convexal Subarachnoid Hem...
- Diagnosis and classification of headache associated with sexual activi...
- Reversible cerebral vasoconstriction syndrome: A narrative review for ...
- Reversible cerebral vasoconstriction syndrome in children: an update
- Outcomes Among Patients With Reversible Cerebral Vasoconstriction Synd...
- Reversible cerebral vasoconstriction syndrome (RCVS): an interesting c...
- Posterior Reversible Encephalopathy Syndrome and Reversible Cerebral V...
- Early Risk of Readmission Following Hospitalization for Reversible Cer...
- Reply to the letter to the editor regarding “predictors and outcomes o...
- Le syndrome de vasoconstriction cérébrale réversible en 2021
- Circulating microRNAs Associated With Reve...
- Hemorrhagic reversible cerebral vasoconstriction syndrome: A retrospec...
- Narrative Review: Headaches After Reversible Cerebral Vasoconstriction...
- Reversible Cerebral Vasoconstriction Syndrome Induced by Blood Transfu...
- Current Treatment Options in Cardiovascular Medicine: Update on Revers...
- Medikamenteninduziertes reversibles zerebrales Vasokonstriktionssyndro...
- Thunderclap headache and reversible cerebral vasoconstriction syndrome...
- Imaging of Non-atherosclerotic Vasculopathies
- No Association of RNF213 Polymorphism with...
- The clinical spectrum of reversible cerebral vasoconstriction syndrome...
- Effect of Nimodipine Treatment on the Clinical Course of Reversible Ce...
- Influence of Climate on the Incidence of RCVS – A Retrospective Study ...
- Reversible Cerebral Vasoconstriction Syndrome Misdiagnosed as Moyamoya...
- Reversible Cerebral Vasoconstriction Syndrome Diagnosed by Visual Symp...
- Reversible cerebral vasoconstriction with thunderclap headache
- Thunderclap headache: an update
- Vascular wall imaging in reversible cerebral vasoconstriction syndrome...
- Primary angiitis of the CNS and reversible cerebral vasoconstriction s...
- Reversible Cerebral Vasoconstriction Syndrome Associated with Severe A...
- Fatal reversible cerebral vasoconstriction syndrome
Figures and tables
Figures & Media
Tables
View Options
View options
PDF/ePub
View PDF/ePubGet access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
IHS members can access this journal content using society membership credentials.
IHS members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
